rcticZymes Technologies - Primary insider trading

11 Nov 2024 15:14 CET

(Tromsø 11 November 2024) Olav Lanes,  VP R&D and applications has on 11
November purchased 5.000 shares in ArcticZymes Technologies ASA for NOK 13,90
per share. Following this transaction holds Mr. Lanes 7.000 shares and 100.000
options in the company.

Marit Sjo Lorentzen, VP Operations has on 11 November purchased 5.000 shares in
ArcticZymes Technoloiges ASA for NOK 13.88 per share. Following this transaction
holds Mrs. Lorentzen 25.331 shares and 100,000 options in the company.

This information is subject to the disclosure requirements in articles 19 of the
Regulation EU 596/2014 (the EU Market Abuse Regulation) and section 5-12 of the
Norwegian Securities Trading Act.

For additional information, please contact
Børge Sørvoll
CFO
+4795290187
ir@arcticzymes.com

About ArcticZymes Technologies ASA

ArcticZymes Technologies is a Norwegian life sciences company focused on the
development, manufacturing and commercialization of novel recombinant enzymes
for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing.

Listed on the Oslo Stock Exchange since 2005 originally under the [AZT] ticker.
Its headquarters are based in Tromsø, Norway, at the SIVA Innovation Centre.
ArcticZymes Technologies' IP and capabilities are protected via a large
portfolio of patents.

For more information, please visit the website: www.arcticzymes.com

More information:
Access the news on Oslo Bors NewsWeb site

631855_Notification_trading_Olav_Lanes.pdf
631855_Notification_trading_Marit_Sjo_Lorentzen.pdf